NASDAQ:IMGN
ImmunoGen, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.immunogen.comipo date
Nov 17, 1989
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that...Show More
Earnings
Earnings Release in 2 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus